Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a new clinical subtype of breast cancer, benefiting from ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

The 2024 NCCN guideline recommend non-platinum cytotoxic drugs and targeted monotherapy ... JSKN003 is an anti-HER2 bispecific ADC, which is developed inhouse with Alphamab's proprietary Glycan ...

there is only one oral anti-HER2 drug on the market, Pfizer's Tukysa (tucatinib), although, that is only approved for HER2-positive breast and colorectal cancers. Another oral HER2 agent ...

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...

Aromatase inhibitors are the most effective endocrine agents for the treatment of ... might be overcome by inhibiting the HER2 pathway Anti-ER/HER2 concurrent treatment provides significantly ...

Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 blockade combined with taxane chemotherapy.

The 2024 NCCN guideline recommend non-platinum cytotoxic drugs and targeted monotherapy as the preferred treatment option for ... highlighting an urgent need for new treatment options. JSKN003 is an ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...